Also found in: Medical.
FFAR1Free Fatty Acid Receptor 1
References in periodicals archive ?
This finding suggests a therapeutic advantage of agents targeting FFAR1, compared with sulphonylureas, which are associated with frequent occurrence of hypoglycemia.
FFAR1 agonists are "'different and interesting" in that they may be capable of restricted initiation of insulin secretion, and "will mainly potentiate nutrient-induced insulin secretion, which will favor enhanced prandial insulin secretion and reduce the risk of interprandial hypoglycemia," Dr.
The durability of incretin-mediated treatments awaits thorough evaluation, and now FFAR1 agonists join that waiting list," he said.